<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314208</url>
  </required_header>
  <id_info>
    <org_study_id>C14-04</org_study_id>
    <nct_id>NCT02314208</nct_id>
  </id_info>
  <brief_title>Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5</brief_title>
  <acronym>SPA-M</acronym>
  <official_title>Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to study the efficacy of three candidate molecules (Xenbilox,&#xD;
      Tahor and Resveratrol) in order to decrease the production of oxysterols by reducing the&#xD;
      synthesis of cholesterol and/or regulate the production of bile acids and/or enabling&#xD;
      neuroprotective action within the motor neuron.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is:&#xD;
&#xD;
      - decrease the accumulation of metabolites which can have a negative impact on neurological&#xD;
      and systemic function of patients with SPG5.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  confirm the clinical and biological tolerance of the different candidate molecules under&#xD;
           study&#xD;
&#xD;
        -  improve the serum bile acid profile of patients with SPG5&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of 27-hydroxycholesterol blood level after 2 months of treatment for each treatment</measure>
    <time_frame>2 months</time_frame>
    <description>27-hydroxycholesterol will be measured on fasten blood samples for the 12 patients included before and after the 2-month treatment period for each treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modification of the serum acid profile after a 2-month treatment measured in blood and urine samples</measure>
    <time_frame>2 months</time_frame>
    <description>In blood and urines samples of the 12 patients, the following criteria will be assesed in order to observe an evolution of the acid profile:&#xD;
total biliary acids&#xD;
ratio of primary/secondary biliary acids&#xD;
the ratio cholic acids/chenodeoxycholic acids&#xD;
the ratio chenodeoxycholic acids/ lithocholic acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 25-hydroxycholesterol blood level after 2 months of treatment for each treatment</measure>
    <time_frame>2 months</time_frame>
    <description>25-hydroxycholesterol will be measured on fasten blood samples for the 12 patients included before and after the 2-month treatment period for each treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events related with digestive problems</measure>
    <time_frame>18 months</time_frame>
    <description>During the study, adverse events related with digestive problems will be evaluate in order to asses the clinical tolerance to each treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of partcipants with adverse events related with standard biological parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Biological tolerance will be evaluate on patients blood samples at each visit. The following criteria will be assessed:&#xD;
ionogram and fasting glucose&#xD;
kidney and liver function with urea, creatinine,lipase, amylase, bilirubine, creatine phosphokinase, transaminases,sodium, potassium, calcium, phosphorus</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Spastic Paraplegia, Hereditary</condition>
  <arm_group>
    <arm_group_label>Xenbilox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resveratrol 80mg capsule by mouth every day for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tahor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenbilox</intervention_name>
    <arm_group_label>Xenbilox</arm_group_label>
    <other_name>Chenodeoxycholic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tahor</intervention_name>
    <arm_group_label>Tahor</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients that have confirmed through genetic testing their status as carriers of 2&#xD;
             mutations in the CYP7B1 gene&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  patients that have signed the informed consent form&#xD;
&#xD;
          -  presence of health care coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hypersensitvity to chenodeoxycholic acid, atorvastatin, resveratrol or to any of&#xD;
             their byproducts&#xD;
&#xD;
          -  cholesterol lowering medications other than the study treatment&#xD;
&#xD;
          -  hepatic failure with transaminases &gt;3 times the normal level&#xD;
&#xD;
          -  progressive biliary pathology&#xD;
&#xD;
          -  chronic diarrhea&#xD;
&#xD;
          -  serious mental illness&#xD;
&#xD;
          -  significant comorbid neurological disorder&#xD;
&#xD;
          -  incapacity to understand information about the protocol&#xD;
&#xD;
          -  unwilling or unable to participate in any part of the study&#xD;
&#xD;
          -  participation in another clinical trial during the study period&#xD;
&#xD;
          -  person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  adult subject under legal protection or unable to consent&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  lack of health care coverage&#xD;
&#xD;
          -  absence of a signed informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny MOCHEL, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spastic paraplegia</keyword>
  <keyword>metabolism</keyword>
  <keyword>oxysterols</keyword>
  <keyword>neurogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

